Logo


Group_29.png

Repherans noktası

Eylül 2021 yayın taraması

Tedaviye özel yayınlar

Riociguat

KTEPH

1. Yang S et al. Haemodynamic effects of riociguat in CTEPH and PAH: A 10-year observational study. ERJ Open Res. 2021;7(3). PMID:34513985.

Genel PH tedavisi

PH

2. Arevalo C et al. Vasodilator use in precapillary pulmonary hypertension with end stage kidney disease: A single center experience. Respir Med. 2021;188:106596 [Epub]. PMID:34509135.

Akciğer hastalıkları ve/veya hipoksiye bağlı PH (Grup 3) 

3. Keen JL, Thenappan T. Shifting gears: The search for group 3 pulmonary hypertension treatment. (Review) Curr Opin Pulm Med. 2021;27(5):296-302. PMID:34175858.

KTEPH ve diğer pulmoner arter obstrüksiyonları (Grup 4) 

4. Chen Y et al. Comparative efficacy and safety of targeted therapies for chronic thromboembolic pulmonary hypertension: A systematic review and network meta-analysis. (Review) Can Respir J. 2021;2021:1626971. PMID:34512819.

Pediatrik PAH 

5. Gorenflo M, Ziesenitz VC. Treatment of pulmonary arterial hypertension in children. (Review) Cardiovasc Diagn Ther. 2021;11(4):1144-59. PMID:34527540.

Non-farmakolojik

PH 

6. Mandurino-Mirizzi A et al. Haemodynamic impact of MitraClip in patients with functional mitral regurgitation and pulmonary hypertension. Eur J Clin Invest. 2021:e13676 [Epub]. PMID:34487548.

PAH 

7. Minhas J et al. Physical activity and its association with traditional outcome measures in pulmonary arterial hypertension. Ann Am Thorac Soc. 2021 [Epub]. PMID:34473938. 

8. Raju SN et al. Pulmonary arterial dilatation: Imaging evaluation using multidetector computed tomography. (Review) Indian J Radiol Imaging. 2021;31(2):409-20. PMID:34556926.

KTEPH ve diğer pulmoner arter obstrüksiyonları (Grup 4) 

9. Bhosle KN, Paul S, Nagre SW. Proposition of quantitative parameters for pre- and early post-operative assessment in pulmonary thromboendarterectomy - An Indian prospective study. Asian Cardiovasc Thorac Ann. 2021 [Epub]. PMID:34541877.

10. Minatsuki S et al. Characteristics and in-hospital outcomes of patients undergoing balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: A time-trend analysis from the Japanese nationwide registry. Open Heart. 2021;8(2). PMID:34521747.

11. Orhan G et al. Surgical results of chronic thromboembolic pulmonary endarterectomy in our recently developed program. Turk Gogus Kalp Damar Cerrahisi Derg. 2021;29(3):295-303. PMID:34589247. 

12. Scudeller PG et al. Chronic thromboembolic pulmonary hypertension: The impact of advances in perioperative techniques in patient outcomes. J Bras Pneumol. 2021;47(5):e20200435. PMID:34495254. 

13. Shigetoshi M et al. Oxygen inhalation can selectively dilate pulmonary arteries in patients with chronic thromboembolic pulmonary hypertension before balloon angioplasty. J Cardiol. 2021 [Epub]. PMID:34563438

 14. Michaud E, Pan M, Aggarwal V. Catheter-based therapies in acute and chronic pulmonary embolism. (Review) Curr Opin Cardiol. 2021 [Epub]. PMID:34508032. 

15. Papakonstantinou N et al. Surgical treatment of pulmonary embolism and chronic thromboembolic pulmonary hypertension. (Review) Curr Pharm Des. 2021 [Epub]. PMID:34477511. 

16. Shimokawahara H, Ogawa A, Matsubara H. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: Advances in patient and lesion selection. (Review) Curr Opin Pulm Med. 2021;27(5):303-10. PMID:34224432.

Pediatrik PAH 

17. Siaplaouras J et al. Effects of exercise training on heart rate variability in children and adolescents with pulmonary arterial hypertension: A pilot study. Cardiovasc Diagn Ther. 2021;11(4):1028-36. PMID:34527528. 

18. Sommer W, Warnecke G. Lung transplantation for pediatric pulmonary arterial hypertension - quo vadis? (Review) Cardiovasc Diagn Ther. 2021;11(4):1178-89. PMID:34527542.

Etiyolojiye özel yayınlar

Pulmoner hipertansiyon

Genel PH

19. Björkman A et al. Accuracy and diagnostic performance of doppler echocardiography to estimate mean pulmonary artery pressure in heart failure. Echocardiography. 2021 [Epub]. PMID:34510533.

20. Chen DD et al. Serum cartilage oligomeric matrix protein is decreased in patients with pulmonary hypertension: A potential protective factor. Pulm Circ. 2021;11(4):0271678x20978861. PMID:34603688.

21. Hardacre CJ et al. Diagnostic test accuracy of artificial intelligence analysis of cross-sectional imaging in pulmonary hypertension: A systematic literature review. Br J Radiol. 2021:20210332 [Epub]. PMID:34541861.

22. Weber L et al. Hemodynamics prior to valve replacement for severe aortic stenosis and pulmonary hypertension during long-term follow-up. J Clin Med. 2021;10(17). PMID:34501326.

23. Xu J et al. Right ventricular shape feature quantification for evaluation of pulmonary hypertension: Feasibility and preliminary associations with clinical outcome submitted for publication. J Biomech Eng. 2021 [Epub]. PMID:34549255.

24. Barbeau S et al. Mechanosensitivity in pulmonary circulation: Pathophysiological relevance of stretch-activated channels in pulmonary hypertension. (Review) Biomolecules. 2021;11(9). PMID:34572602.

25. Vahdatpour CA et al. Advanced airway management and respiratory care in decompensated pulmonary hypertension. (Review) Heart Fail Rev. 2021:1-11 [Epub]. PMID:34476657.

İlişkili PH

26. Edmonston DL et al. Noninvasive risk score to screen for pulmonary hypertension with elevated pulmonary vascular resistance in diseases of chronic volume overload. Am J Cardiol. 2021 [Epub]. PMID:34497006.

27. Jiang X et al. Clinical features and survival in Takayasu’s arteritis-associated pulmonary hypertension: A nationwide study. Eur Heart J. 2021 [Epub]. PMID:34506618.

28. Fukumoto Y. Takayasu arteritis-associated pulmonary hypertension. (Editorial) Eur Heart J. 2021 [Epub]. PMID:34542609.

29. Young A et al. Performance of the DETECT algorithm for pulmonary hypertension screening in a systemic sclerosis cohort. Arthritis Rheumatol. 2021;73(9):1731-7. PMID:33760392.

30. Zhang Y et al. Diagnostic value of cardiac natriuretic peptide on pulmonary hypertension in systemic sclerosis: A systematic review and meta-analysis. Joint Bone Spine. 2021:105287 [Epub]. PMID:34601113.

Akciğer hastalıkları ve/veya hipoksiye bağlı PH (Grup 3)

31. Furian M et al. Markers of cardiovascular risk and their reversibility with acute oxygen therapy in Kyrgyz highlanders with high altitude pulmonary hypertension. Pulmonology. 2021;27(5):394-402. PMID:33674243.

Belirsiz ve/veya çok faktörlü mekanizmalara sahip PH (Grup 5)

32. Gallini JW et al. Pulmonary hypertension: A new vascular complication of diabetes? Chest. 2021 [Epub]. PMID:34537188.

Pediatrik PH

33. Lammers AE, Apitz C. Update from the World Symposium on Pulmonary Hypertension 2018: Does the new hemodynamic definition of pediatric pulmonary hypertension have an impact on treatment strategies? Cardiovasc Diagn Ther. 2021;11(4):1048-51. PMID:34527530.

34. Morgan RW et al. Pulmonary hypertension among children with in-hospital cardiac arrest: A multicenter study. Resuscitation. 2021;168:52-7 [Epub]. PMID:34536558.

35. Herberg U et al. Altitude exposure in pediatric pulmonary hypertension - are we ready for (flight) recommendations? (Review) Cardiovasc Diagn Ther. 2021;11(4):1122-36. PMID:34527538.

36. Kaestner M, Apitz C, Lammers AE. Cardiac catheterization in pediatric pulmonary hypertension: A systematic and practical approach. (Review) Cardiovasc Diagn Ther. 2021;11(4):1102-10. PMID:34527536.

37. Lammers AE et al. A guide to echocardiographic assessment in children and adolescents with pulmonary hypertension. (Review) Cardiovasc Diagn Ther. 2021;11(4):1160-77. PMID:34527541.

38. Latus H, Meierhofer C. Role of cardiovascular magnetic resonance in pediatric pulmonary hypertension-novel concepts and imaging biomarkers. (Review) Cardiovasc Diagn Ther. 2021;11(4):1057-69. PMID:34527532.

COVID-19 ve PH

39. Cascino TM, Desai AA, Kanthi Y. At a crossroads: Coronavirus disease 2019 recovery and the risk of pulmonary vascular disease. Curr Opin Pulm Med. 2021;27(5):342-9. PMID:34127622.

40. Cueto-Robledo G et al. Severe pulmonary hypertension: An important sequel after severe post-acute COVID-19 pneumonia. (Review) Curr Probl Cardiol. 2021:101004 [Epub]. PMID:34601005.

Pulmoner arteriyel hipertansiyon (Grup 1)

Genel PAH

41. Helgeson SA et al. Facemasks and walk distance in pulmonary arterial hypertension patients. Mayo Clin Proc Innov Qual Outcomes. 2021;5(5):835-8. PMID:34485828.

42. Kramer T et al. Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: A long-term study. J Cachexia Sarcopenia Muscle. 2021 [Epub]. PMID:34498427.

43. Lattanzio M et al. Assessment of right ventricle in pulmonary arterial hypertension with three-dimensional echocardiography and cardiovascular magnetic resonance. J Cardiovasc Med (Hagerstown). 2021. PMID:34482325.

44. Rahaghi FN et al. Evolution of obstructive lung function in advanced pulmonary arterial hypertension. Am J Respir Crit Care Med. 2021 [Epub]. PMID:34555310.

45. Wieteska-Miłek M et al. Fear of COVID-19, anxiety and depression in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension during the pandemic. J Clin Med. 2021;10(18). PMID:34575303.

46. Deshwal H, Weinstein T, Sulica R. Advances in the management of pulmonary arterial hypertension. (Review) J Investig Med. 2021;69(7):1270-80. PMID:34580123.

47. El-Kersh K, Dickinson JD. Pulmonary arterial hypertension: Promising advances and remaining challenges. (Editorial) J Investig Med. 2021;69(7):1268-9. PMID:34580122.

48. Evans CE et al. Endothelial cells in the pathogenesis of pulmonary arterial hypertension. (Review) Eur Respir J. 2021;58(3). PMID:33509961.

49. Wu Y et al. The pathophysiological role of novel pulmonary arterial hypertension gene SOX17. (Review) Eur Respir J. 2021;58(3). PMID:33632800.

İdiyopatik PAH

50. Luo C et al. Liver dysfunction in idiopathic pulmonary arterial hypertension: Prevalence, characteristics and prognostic significance, a retrospective cohort study in China. BMJ Open. 2021;11(9):e045165. PMID:34493501.

İlişkili PAH

51. Rallidis LS et al. Low-dose dobutamine stress echocardiography for the early detection of pulmonary arterial hypertension in selected patients with systemic sclerosis whose resting echocardiography is non-diagnostic for pulmonary hypertension. J Clin Med. 2021;10(17). PMID:34501420.

52. Jansen K et al. Pulmonary arterial hypertension in adults with congenital heart disease: Markers of disease severity, management of advanced heart failure and transplantation. (Review) Expert Rev Cardiovasc Ther. 2021;19(9):837-55. PMID:34511015.

Pediatrik PAH

53. Dufva MJ et al. Ventricular-vascular coupling is predictive of adverse clinical outcome in paediatric pulmonary arterial hypertension. Open Heart. 2021;8(2). PMID:34583983.

54. García-Aguilar H et al. Healthcare resource utilization and costs in pediatric pulmonary arterial hypertension in a third-level hospital in Mexico. J Comp Eff Res. 2021 [Epub]. PMID:34585624.

55. Machado R et al. Biallelic variants of ATP13A3 cause dose-dependent childhood-onset pulmonary arterial hypertension characterised by extreme morbidity and mortality. J Med Genet. 2021 [Epub]. PMID:34493544.

Sol kalp hastalığına bağlı PH (Grup 2)

56. Gumauskiene B et al. The association of left ventricular histologically verified myocardial fibrosis with pulmonary hypertension in severe aortic stenosis. Perfusion. 2021 [Epub]. PMID:34524051.

57. Mazimba S et al. Pulmonary Artery Proportional Pulse Pressure (PAPP) index identifies patients with improved survival from the CardioMEMS implantable pulmonary artery pressure monitor. Heart Lung Circ. 2021;30(9):1389-96. PMID:33863665.

Akciğer hastalıkları ve/veya hipoksiye bağlı PH (Grup 3)

58. Behr J, Nathan SD. Pulmonary hypertension in interstitial lung disease: Screening, diagnosis and treatment. Curr Opin Pulm Med. 2021;27(5):396-404. PMID:34127619.

59. Girgis RE, Hoeper MM. Pulmonary hypertension in fibrosing idiopathic interstitial pneumonia: Uncertainties, challenges and opportunities. J Heart Lung Transplant. 2021;40(9):872-81. PMID:33832831.

KTEPH ve diğer pulmoner arter obstrüksiyonları (Grup 4)

60. Al-Otaibi M et al. May-Thurner anatomy in patients with chronic thromboembolic pulmonary hypertension: An important clinical association. JACC Cardiovasc Interv. 2021;14(17):1940-6. PMID:34503745.

61. Kostrubiec M. May-Thurner anatomy: An undervalued anatomical variant in patients with chronic thromboembolic pulmonary hypertension? (Editorial) JACC Cardiovasc Interv. 2021;14(17):1947-9. PMID:34503746.

62. Cruz-Utrilla A et al. Sex differences in chronic thromboembolic pulmonary hypertension. Treatment options over time in a national referral center. J Clin Med. 2021;10(18). PMID:34575363.

63. Frederiksen CA et al. Reverse remodeling of tricuspid valve morphology and function in chronic thromboembolic pulmonary hypertension patients following pulmonary thromboendarterectomy: A cardiac magnetic resonance imaging and invasive hemodynamic study. BMC Cardiovasc Disord. 2021;21(1):450. PMID:34535073.

64. Kanwar MK et al. Development and validation of a claims-based model to identify patients at risk of chronic thromboembolic pulmonary hypertension following acute pulmonary embolism. Curr Med Res Opin. 2021;37(9):1483-91. PMID:34166172.

65. Li Y et al. Right ventricular function predicts adverse clinical outcomes in patients with chronic thromboembolic pulmonary hypertension: A three-dimensional echocardiographic study. Front Med (Lausanne). 2021;8:697396. PMID:34497813.

66. Maschke S et al. Motion reduction for C-Arm computed tomography of the pulmonary arteries: Image quality of a motion correction algorithm in patients with chronic thromboembolic hypertension during balloon pulmonary angioplasty. Rofo. 2021;193(9):1074-80. PMID:33634459.

67. Munshi RF et al. Impact of pulmonary hypertension in patients with acute exacerbation of chronic obstructive pulmonary disease and its effect on healthcare utilization. Pulm Circ. 2021;11(4):20458940211046838. PMID:34594546.

68. Tura-Ceide O et al. Derivation and characterisation of endothelial cells from patients with chronic thromboembolic pulmonary hypertension. Sci Rep. 2021;11(1):18797. PMID:34552142.

Belirsiz ve/veya çok faktörlü mekanizmalara sahip PH (Grup 5)

69. Samaranayake CB et al. Sarcoidosis associated pulmonary hypertension: An update. Curr Opin Pulm Med. 2021;27(5):285-95. PMID:34127623.

SSc-DU

70. Cox M, Hughes M. Osteomyelitis complicating digital ulcer disease. J Clin Rheumatol. 2021;27(6):e230-e1. PMID:31977650.

71. Leask A. Blisters on your fingers. J Cell Commun Signal. 2021;15(3):465-6. PMID:34014499.








Hazırlama tarihi: Kasım 2021

CP-279820